Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Completed dose-escalation portion of the ongoing Phase 1 study of NTLA-2001 in patients with transthyretin amyloidosis with cardiomyopathy; expects to present interim safety and serum TTR reduction... | August 4, 2022

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Ian Karp ,Alina Li ,Rebecca Spalding ,John Leonard ,Regeneron Pharmaceuticals Inc ,Bridge Communications ,Company At The Market ,Twitter ,Intellia Therapeutics Inc ,Nasdaq ,Exchange Commission ,Vivo Program Updates ,Corporate Communications ,Globenewswire Inc ,Intellia President ,Chief Executive Officer ,Recent Operational ,Regeneron Pharmaceuticals ,European Association ,Liver International Congress ,Investigational New Drug ,Myeloid Leukemia ,Wilm Tumor ,Pipeline Expansion ,Discuss Second Quarter ,Private Securities Litigation Reform Act ,Vice President ,Investor Relations ,Intellia Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Ompleted ,Portion ,F ,The ,Ngoing ,Hase , ,Study ,N ,Patients ,Ith ,Transthyretin ,Amyloidosis ,Xpects ,O ,Present ,Interim ,Safety ,End ,Serum ,Tr Ntla Us45826j1051 ,